The global veterinary vaccines market was valued at USD 10.73 Billion in 2024 and is expected to grow at a CAGR of 6.20%, reaching USD 19.58 Billion by 2034. The market is driven by growing awareness of animal health, increasing pet ownership, and widespread livestock vaccination programs. Rising demand for animal-derived food products and advancements in biotechnology are enhancing vaccine effectiveness. Supportive government initiatives and increasing R&D investment are expected to boost growth in the forecast period, along with innovations in oral and DNA-based vaccines.
Base Year
Historical Period
Forecast Period
In June 2025, EMA recommended approval of Biobhyo, the first vaccine for swine dysentery in the EU. This advancement is expected to enhance disease control in livestock, thereby positively influencing the market growth.
One of the major market drivers includes strategic acquisitions to expand vaccine portfolios. For instance, in July 2024, Merck Animal Health acquired Elanco’s aqua business, enhancing its position in aquatic vaccines and sustainable fish health solutions.
In 2024, Mazen Animal Health advanced its oral vaccine platform using corn-based biofactories, backed by state grants and investor funding, an innovation expected to significantly drive growth in the market.
Compound Annual Growth Rate
6.2%
Value in USD Billion
2025-2034
*this image is indicative*
Veterinary vaccines play a crucial role in promoting animal health by preventing the spread of infectious diseases among livestock and companion animals, thereby supporting food security and public health. These vaccines contribute significantly to reducing the need for antibiotics, enhancing animal productivity, and improving overall welfare. The market has been witnessing consistent growth due to rising pet adoption, increasing livestock populations, and growing awareness of zoonotic diseases. Advancements in vaccine technology and government initiatives to control disease outbreaks further support market expansion. The market was valued at USD 10.73 Billion in 2024, reflecting its increasing importance in the animal healthcare industry.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Rising Disease Prevalence in Carnivores to Accelerate Market Growth
The increasing incidence of infectious diseases among small carnivores is a significant growth driver of the market. A study published in January 2024 by Jian Liang et al. reported that 22.6% of 8,582 tested minks, foxes, and raccoon dogs across 12 countries were positive for Canine Distemper (CD). South Korea exhibited the highest regional prevalence at 65.8%. This alarming infection rate highlights the urgent need for effective vaccination strategies. The growing emphasis on disease prevention is expected to drive continued market expansion.
Some of the notable trends in the market include regulatory advancements that support innovation in animal health and the expansion of advanced manufacturing facilities.
Regulatory Advancements Supporting Animal Health Innovation to Boost Market Expansion
The market is witnessing growth driven by evolving regulatory frameworks that support innovation in animal health. In October 2024, the U.S. FDA’s Center for Veterinary Medicine (CVM) initiated a structural reorganization to enhance its One Health approach and improve regulatory efficiency. By streamlining approval processes, such as conditional approvals and indexing, this regulatory shift will likely foster faster development and legal marketing of novel veterinary vaccines, especially for emerging diseases and minor species. These developments are expected to reinforce market growth in the coming years.
Expansion of Advanced Manufacturing Facilities to Strengthen Veterinary Vaccines Market Value
The increasing focus on innovation and large-scale vaccine production is driving a significant shift in the market. In November 2024, Ceva Animal Health, the fifth-largest global animal health company, announced the construction of a state-of-the-art 7,000 m² vaccine manufacturing plant in Monor, Hungary. This facility will produce fermentation-based multicomponent inactivated vaccines and is expected to deliver over 8 billion doses annually. Such strategic investments are anticipated to strengthen preventive animal healthcare and propel market growth over the coming years.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Live Attenuated Vaccines to Lead the Market Share by Product
The market is segmented by product into live attenuated vaccines, inactivated vaccines, recombinant vaccines, and others. Among these, live attenuated vaccines are expected to dominate the market owing to their ability to induce strong, long-lasting immune responses with fewer doses. For example, in June 2025, Vietnam’s AVAC ASF LIVE, the world’s first commercialized live attenuated vaccine for African Swine Fever, was exported to Indonesia, marking its first international shipment and highlighting its growing global demand. Such innovations underscore the growing preference for live attenuated formulations in the global effort to control infectious animal diseases effectively.
The regions included in the report are North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. Among these, North America is expected to hold a substantial share in the market, driven by high veterinary healthcare spending, established regulatory frameworks, and technological advancements. For instance, in November 2024, a notable initiative, the WSU-led Feed the Future Veterinary Vaccine Delivery Innovation Lab, was launched with up to USD 35 million in USAID funding. The program aims to improve vaccine delivery and adoption in Kenya, Tanzania, and Nepal by overcoming cold chain limitations and strengthening local veterinary systems. Such efforts underscore the region's pivotal role in advancing global animal health.
The key features of the market report comprise patent analysis, grant analysis, clinical trials analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Pfizer Inc., a leading biopharmaceutical company, significantly strengthened its presence in the market through the acquisition of Wyeth and its subsidiary, Fort Dodge Animal Health. This strategic move expanded Pfizer Animal Health’s diverse portfolio across livestock, poultry, equine, and companion animals. Notable products include Bovi-Shield® Gold, Suvaxyn®, Poulvac®, and Lymevax®, reinforcing its position as a global leader in veterinary vaccine innovation and distribution.
Cargill, Incorporated plays a significant role in the veterinary vaccines market through its active promotion of newborn calf vaccine protocols. The company emphasizes timely vaccinations, including for Foot and Mouth Disease (FMD), Haemorrhagic Septicaemia, Theileriosis, and Brucellosis, to reduce calf mortality and enhance herd productivity. Cargill’s commitment to preventive healthcare supports healthier livestock and more profitable dairy farming operations.
Boehringer Ingelheim International GmbH, through its Animal Health division, plays a significant role in the market. The company offers a robust portfolio of vaccines and therapeutics for pets, equine, cattle, poultry, and swine, widely recognized for their quality and effectiveness. Committed to innovation and disease prevention, Boehringer Ingelheim enhances animal and human well-being through science-driven veterinary solutions.
Zoetis Inc., the world’s leading animal health company, has years of experience in advancing animal care through innovative solutions. With a strong global presence in various countries, Zoetis develops and markets a broad portfolio of veterinary vaccines, medicines, diagnostics, and technologies. Its recent focus includes leveraging artificial intelligence to enhance vaccine development, reaffirming its commitment to the evolving needs of the global veterinary vaccines market.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market are Bayer AG, Sanofi, GSK plc, Merck & Co., Inc., Takeda Pharmaceutical Company Limited, and Elanco, among others.
The EMR’s report titled “Veterinary Vaccines Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
Market Breakup by Product
Market Breakup by Animal
Market Breakup by Route of Administration
Market Breakup by Distribution Channel
Market Breakup by End User
Market Breakup by Region
Upto 15% Off
USD
$3299 $2969
$5499 $4949
$6999 $5949
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2024 |
| Historical Period | 2018-2024 |
| Forecast Period | 2025-2034 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product |
|
| Breakup by Animal |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channel |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share